Endovia Health Sciences (EDVA) Revenue Growth (3y) (2015 - 2026)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Revenue Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.50 Bn | 133.65 Bn | 2.84 Bn | 10.17% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 10.76% |
| 3 | Argenx Se | 65.05 Bn | 59.86 Bn | 1.37 Bn | 77.85% |
| 4 | Moderna | 57.11 Bn | 51.98 Bn | 52.00 Mn | -25.02% |
| 5 | Revolution Medicines | 44.71 Bn | 44.71 Bn | - | - |
| 6 | BeOne Medicines | 40.40 Bn | 35.31 Bn | 1.53 Bn | 42.02% |
| 7 | Alnylam Pharmaceuticals | 35.36 Bn | 32.05 Bn | 992.69 Mn | 59.40% |
| 8 | Royalty Pharma | 28.16 Bn | 27.32 Bn | - | 7.80% |
| 9 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 76.62% |
| 10 | Endovia Health Sciences | 801,166.21 | 558,464.21 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -91.01% |
| Dec 31, 2025 | -27.57% |
| Sep 30, 2025 | -56.78% |
| Jun 30, 2025 | -26.10% |
| Mar 31, 2025 | -74.05% |
| Dec 31, 2024 | -44.38% |
| Sep 30, 2024 | -30.70% |
| Jun 30, 2024 | -32.71% |
| Mar 31, 2024 | -11.07% |
| Dec 31, 2023 | 35.43% |
| Sep 30, 2023 | 95.07% |
| Jun 30, 2023 | 132.62% |
| Mar 31, 2023 | 273.22% |
| Dec 31, 2022 | 466.15% |
| Sep 30, 2022 | 151.76% |
| Jun 30, 2022 | 372.03% |
| Mar 31, 2022 | 1,037.90% |
| Dec 31, 2021 | 109.83% |
| Sep 30, 2021 | 111.24% |
| Jun 30, 2021 | 113.15% |